Pages that link to "Q79451253"
Jump to navigation
Jump to search
The following pages link to Efficacy and safety of 3-day azithromycin versus 5-day moxifloxacin for the treatment of acute bacterial exacerbations of chronic bronchitis (Q79451253):
Displaying 9 items.
- Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes (Q28243911) (← links)
- Zabofloxacin versus moxifloxacin in patients with COPD exacerbation: a multicenter, double-blind, double-dummy, randomized, controlled, Phase III, non-inferiority trial (Q36213054) (← links)
- Use of azithromycin in the treatment of acute exacerbations of COPD. (Q37115885) (← links)
- Efficacy and safety of moxifloxacin in acute exacerbations of chronic bronchitis and COPD: a systematic review and meta-analysis (Q37629535) (← links)
- The diagnosis and treatment of elderly patients with acute exacerbation of chronic obstructive pulmonary disease and chronic bronchitis (Q37732428) (← links)
- Review of Macrolides (Azithromycin, Clarithromycin), Ketolids (Telithromycin) and Glycylcyclines (Tigecycline) (Q37890576) (← links)
- Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases. (Q37959271) (← links)
- Network meta-analysis of success rate and safety in antibiotic treatments of bronchitis (Q41405351) (← links)
- JAID/JSC Guidelines for the Treatment of Respiratory Infectious Diseases: The Japanese Association for Infectious Diseases/Japanese Society of Chemotherapy - The JAID/JSC Guide to Clinical Management of Infectious Disease/Guideline-preparing Committ (Q42102339) (← links)